Latest news with #MarksansPharma
Business Standard
5 days ago
- Business
- Business Standard
Marksans Pharma gets regulatory nod for marketing type-2 diabetes medication in UK
Marksans Pharma said that its UK-based wholly owned subsidiary Relonchem has received marketing authorization for Metformin Hydrochloride oral solution product from UK Medicines & Healthcare Products Regulatory Agency. Metformin Hydrochloride is a widely prescribed medication used for the management of type-2 diabetes, particularly in patients who require oral liquid formulations due to difficulty in swallowing tablets. This regulatory approval would enable Marksans Pharma to market and distribute the said oral solution in the UK. Marksans Pharma is engaged in the research, manufacturing & marketing of generic pharmaceutical formulations in the global markets. The company's manufacturing facilities are approved by several leading regulatory agencies including USFDA, UKMHRA, and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, antidiabetic, pain management, gastroenterological, and anti-allergies. the company is marketing these products globally. The company reported a 25.6% increase in consolidated net profit to Rs 104.56 crore on a 16.3% rise in revenue from operations to Rs 681.85 crore in Q3 FY25 over Q3 FY24. The scrip rose 0.38% to currently trade at Rs 261.35 on the BSE.
Business Standard
20-05-2025
- Business
- Business Standard
Marksans Pharma consolidated net profit rises 15.66% in the March 2025 quarter
Sales rise 26.51% to Rs 708.46 crore Net profit of Marksans Pharma rose 15.66% to Rs 90.55 crore in the quarter ended March 2025 as against Rs 78.29 crore during the previous quarter ended March 2024. Sales rose 26.51% to Rs 708.46 crore in the quarter ended March 2025 as against Rs 560.01 crore during the previous quarter ended March 2024. For the full year,net profit rose 21.32% to Rs 380.58 crore in the year ended March 2025 as against Rs 313.70 crore during the previous year ended March 2024. Sales rose 20.46% to Rs 2622.85 crore in the year ended March 2025 as against Rs 2177.41 crore during the previous year ended March 2024. Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 708.46560.01 27 2622.852177.41 20 OPM % 17.7519.58 - 20.1521.06 - PBDT 138.84121.33 14 587.35497.80 18 PBT 116.09100.28 16 503.97423.53 19 NP 90.5578.29 16 380.58313.70 21
Business Upturn
19-05-2025
- Business
- Business Upturn
Marksans Pharma's UK arm gets marketing approval for Sennosides 7.5 mg tablets
By Aditya Bhagchandani Published on May 19, 2025, 13:27 IST Shares of Marksans Pharma could remain in focus after the company announced that its wholly owned UK subsidiary, Relonchem Limited, has received marketing authorization for Sennosides 7.5 mg tablets from the UK Medicines & Healthcare Products Regulatory Agency (MHRA). This regulatory clearance marks a significant step in the company's product expansion in the UK pharmaceutical market. Sennosides are typically used as a laxative in various therapeutic segments, and the approval strengthens Marksans' position in the gastrointestinal treatment category. Marksans Pharma, headquartered in Mumbai, engages in the research, manufacturing, and marketing of generic pharmaceutical formulations across global markets. Its manufacturing facilities in India, the USA, and the UK are approved by top regulatory bodies, including USFDA, UKMHRA, and Australian TGA. The company's product portfolio spans major therapeutic areas such as cardiovascular, central nervous system, anti-diabetic, pain management, gastroenterological, and anti-allergies. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
&w=3840&q=100)
Business Standard
15-05-2025
- Business
- Business Standard
Here's why Marksans Pharma share price increased over 2% in trade on May 15
Marksans Pharma share price: Pharmaceutical company Marksans Pharma shares rose up to 2.18 per cent to hit an intraday high of ₹243.40 per share on Thursday, May 15, 2025. However, at 11:20 PM, Marksans Pharma shares pared gains and were trading merely 0.08 per cent higher at ₹238 per share. In comparison, BSE Sensex was trading 0.10 per cent lower at 81,247.08 level. Why led to the up move in Marksans Pharma share price? The northward move in Marksans Pharma came after the company's wholly-owned subsidiary, Relonchem, received marketing authorisation for the product Gabapentin 50 mg/ml oral solution from UK Medicines & Healthcare Products Regulatory Agency (UK MHRA). In an exchange filing, Marksans Pharma said, 'Marksans Pharma hereby announces that its wholly owned subsidiary Relonchem Limited has received marketing authorisation for the product Gabapentin 50 mg/ml oral solution from UK Medicines & Healthcare Products Regulatory Agency.' Gabapentin is commonly used to treat epilepsy and nerve pain. In epilepsy, it's believed to work by calming abnormal electrical activity in the brain that leads to seizures. It's also effective for managing nerve pain, which may result from conditions such as diabetes, shingles, or physical injuries. Marksans Pharma results Marksans Pharma will release its March quarter of financial year 2025 (Q4FY25) results on May 19. The board will also consider recommending a dividend on the equity shares for FY25. In Q3FY25, Marksans Pharma's operating revenue stood at ₹681.8 crore, up 16.3 per cent year-on-year (Y-o-Y), driven growth across key markets, led by US region The gross profit stood at ₹383.5 crore, up 22.4 per cent Y-o-Y, with a gross margin expansion of 279 basis points (bps) Y-o-Y to 56.2 per cent. The growth was attributed to softening of raw material prices and a better product mix, the company said in a statement. About Marksans Pharma Marksans Pharma, based in Mumbai, specialises in the research, manufacturing, and marketing of generic pharmaceutical formulations in global markets. The company operates manufacturing facilities in India, the USA, and the UK, all of which are approved by regulatory agencies, including the USFDA, UKMHRA, and Australian TGA. Marksans Pharma offers a diverse product portfolio across key therapeutic areas, such as cardiovascular (CVS), central nervous system (CNS), anti-diabetic, pain management, gastroenterology, and anti-allergies. These products are marketed worldwide.
Business Standard
28-04-2025
- Business
- Business Standard
Marksans Pharma gains as USFDA concludes inspection at New York unit
Marksans Pharma rose 1.9% to Rs 220.10 after the US Food and Drug Administration (USFDA) concluded its inspection of the company's subsidiary, Time-Cap Laboratories Inc. The inspection took place from April 16 to April 24, 2025, at the subsidiary's manufacturing facility in Farmingdale, New York. At the end of the inspection, the subsidiary received one observation, documented in the USFDA's Form 483. Notably, the inspection did not raise any concerns regarding data integrity. Marksans Pharma confirmed that it will work closely with the USFDA to address the observation within the prescribed timeline. Marksans Pharma is engaged in the research, manufacturing & marketing of generic pharmaceutical formulations in the global markets. The company's manufacturing facilities are approved by several leading regulatory agencies including USFDA, UKMHRA, and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, antidiabetic, pain management, gastroenterological, and anti-allergies. the company is marketing these products globally. The company reported a 25.6% increase in consolidated net profit to Rs 104.56 crore on a 16.3% rise in revenue from operations to Rs 681.85 crore in Q3 FY25 over Q3 FY24.
